Sam Banister: Psychedelic Startups, Biotech, Drug Discovery, Psilocybin, DMT, Psychedelics & Society

Nick talks to medicinal chemist Sam Banister, who is co-founder and Chief Science Officer at Psylo, a biotech startup focused on developing next-generation psychedelic medicines. They discuss: the past, present, and future of psychedelic science; Sam's journey from academia to biotech startup co-founder; Alexander Shulgin; psychedelics like psilocybin, DMT, and others; and psychedelics & society.

SUPPORT M&M:
Sign up for the free weekly Mind & Matter newsletter
[https://mindandmatter.substack.com/?s...]

Follow Nick's work through Linktree:
[https://linktr.ee/trikomes]

Athletic Greens, comprehensive daily nutrition (Free 1-year supply Vitamin D w/ purchase)
[https://www.athleticgreens.com/mindan...]

DoubleBlind Magazine, a leading source of news, information, and education about psychedelics. Use code MINDMATTER for 20% site-wide.
[https://www.doubleblindmag.com/mindma...]

Organize your digital highlights & notes w/ Readwise (2 months free w/ sub)[https://readwise.io/nickjikomes/]

0:00:00 Episode Intro
0:04:15 Sam Banister
0:10:03 Serotonin 2B Receptor & Heart Problems
0:15:58 Novel Psychedelic Drug Variants
0:24:03 Stagnation in Psychiatric Drug Development
0:30:41 DMT & DMT Analogues
0:38:20 Starting & Raising Money for Psychedelic Startups
0:47:52 Psychedelic Therapy & Neuroplasticity
0:56:58 Legalization vs. Decriminalization of Psychedelics
1:03:38 Unanswered Questions in Psychedelic Science
1:09:00 Psychedelics & Human Culture